A5102918650- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Growth Hormone and Insulin-like Growth Factors
- Traditional Chinese Medicine Studies
- Adrenal and Paraganglionic Tumors
- Pituitary Gland Disorders and Treatments
- Diabetes Management and Research
- Pancreatic function and diabetes
- Plant-based Medicinal Research
- Health Promotion and Cardiovascular Prevention
- Renal function and acid-base balance
- Natural Antidiabetic Agents Studies
- Peroxisome Proliferator-Activated Receptors
- Clinical Nutrition and Gastroenterology
- Hemodynamic Monitoring and Therapy
- Cardiovascular Health and Risk Factors
- Pharmacology and Obesity Treatment
- Global Public Health Policies and Epidemiology
- Endoplasmic Reticulum Stress and Disease
- Traditional Chinese Medicine Analysis
- Hops Chemistry and Applications
- Cardiac Arrest and Resuscitation
- Medicinal Plants and Bioactive Compounds
- Liver Disease Diagnosis and Treatment
Hebei Medical University
2018-2023
Second Hospital of Hebei Medical University
2018-2023
Fujian Provincial Hospital
2019-2023
Fujian Medical University
2019-2023
Tianjin Beichen Hospital
2012
First Hospital of Shanxi Medical University
2010
Shanxi Medical University
2010
Mazdutide is a once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist. We evaluated the efficacy safety of 24-week treatment mazdutide up to 6 mg in Chinese overweight adults or with obesity, as an interim analysis randomised, two-part (low doses high dose 9 mg), double-blind, placebo-controlled phase 2 trial (ClinicalTrials.gov, NCT04904913). Overweight (body-mass index [BMI] ≥24 kg/m
Chiglitazar (Carfloglitazar) is a novel peroxisome proliferator-activated receptor (PPAR) pan-agonist that has shown promising effects on glycemic control and lipid regulation in patients with type 2 diabetes. In this randomized phase 3 trial, we compared the efficacy safety of chiglitazar sitagliptin diabetes who had insufficient despite strict diet exercise regimen. Eligible were (1:1:1) to receive 32 mg (n = 245), 48 246), or 100 248) once daily for 24 weeks. The primary endpoint was...
Background: The role of thioredoxin-interacting protein (TXNIP) in lipopolysaccharide-induced liver injury mice has been reported, but the underlying mechanisms are poorly understood. Methods: We overexpressed deubiquitinase cells overexpressing TXNIP and then detected level to screen out regulating TXNIP; interaction between was verified by coimmunoprecipitation. After knockdown a overexpression Huh7 HepG2 cells, lipopolysaccharide used establish cellular inflammatory model explore...
Aim To investigate the effectiveness of metformin in delaying or preventing progression to diabetes a Chinese population with impaired glucose regulation (IGR). Materials and methods This multicentre, randomized, open‐label, controlled study (NCT03441750) will assess efficacy over ≥2 years. Eligible participants be randomly assigned (1:1) lifestyle intervention (LSI) plus LSI, stratification based on blood pressure, anti‐hypertensive medication use isolated/non‐isolated fasting glucose. All...
Objective: DBPR108, a novel dipeptidyl-peptidase-4 inhibitor, has shown great antihyperglycemic effect in animal models. This study was to evaluate the efficacy and safety of DBPR108 monotherapy type 2 diabetes mellitus (T2DM).Methods: 12-week, double-blind, placebo-controlled phase II clinical trial. The newly diagnosed or inadequately controlled untreated T2DM patients were randomized receive 50, 100, 200 mg placebo ratio 1:1:1:1. primary outcome HbA1c change from baseline week 12....
Abstract Background Lanreotide autogel is a somatostatin analog (SSA) approved for the treatment of acromegaly in 73 countries worldwide; however, it not yet China. The aim this study was to evaluate efficacy and safety lanreotide compared with 40 mg prolonged release (PR) Chinese patients active acromegaly. Methods LANTERN phase 3, randomized, open-label, non-inferiority study. Patients who had undergone surgery ≥3 months prior, or were unlikely unable undergo surgery, treated 60/90/120...
Objective To evaluate the efficacy and safety of glargine insulin injection (Uslen) in treatment diabetic patients. Methods A multicenter, randomized, open-labeled positive control clinical trial included patients with type 1 or 2 diabetes mellitus having poor glucose after using oral antidiabetic drug short-acting insulin. All were treated Uslen Lantus for 16 weeks two groups by a ratio 1∶1. The decreased value qualification rates glycated hemoglobin A1c(HbA1c) fasting blood (FBG),...
Objective To compare influences of enteral nutrition (EN) and parenteral (PN) on the inflammatory factors immune functions in patients with systemic response syndrome. Methods Totally 85 who were treated First Hospital Shanxi Medical University, Province People's Hospital, Taiyuan Central from April, 2006 to 2010 enrolled this study divided into EN group (n = 49) PN 36) according support modes. The changes after nutritional supports recorded compared between these two groups. Results weight,...
Objective To evaluate the efficacy and safety of miglitol in type 2 diabetic patients with acarbose as control group. Methods A multicenter (in 10 hospitals), open, randomized parallel-controlled clinical trial was carried out from January 2012 to December 2013. A total newly diagnosed 216 cases diabetes [glycosylated hemoglobin A1c (HbA1c): 7%~10%] were treat or acarbose. The initial dose 50 mg three times daily, increased 100 daily according fasting blood glucose (≥ 7.0 mmol/L)....
Up to one-third of patients admitted the ICU are in circulatory shock, and early recognition condition is vital if subsequent tissue injuries be avoided. We would like know what role arterial lactic acid, inferior vena cava variability, CVP (central venous pressure) play stages shock. This a retrospective study who underwent surgical resuscitation Department Critical Care Medicine. use ROC (receiver-operating characteristic) curve evaluate significance each indicator diagnosis. For...
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)
Abstract Background : Numerous studies have found sex disparity in the prevalence of metabolic disorders. However, information is lacking on gender difference among residents north China and little epidemiological data available disorders North China. Methods This cross-sectional study involved 2650 randomly selected adult Hebei province, Demographic, biochemical, physical examination parameters were collected compared between men women. Metabolic disorder was estimated their associations...